Stockscreener 앱 받기
49.57
1.31%
0.64
Novo Nordisk Adr 주식(NVO)의 최신 뉴스
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Where is Novo Nordisk A/S (NVO) Headed? - Finviz
Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz
Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz
Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm
Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm
Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz
Is Novo Nordisk Stock a Bargain Right Now? - Finviz
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? - Finviz
Novo Nordisk Oral Wegovy Launch Reshapes Obesity Access And Valuation Outlook - Sahm
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - Finviz
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz
5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com
Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm
0.82%
자본화:
|
볼륨(24시간):